Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 29, Number 8—August 2023
CME ACTIVITY - Synopsis

Healthcare-Associated Infections Caused by Mycolicibacterium neoaurum

Kate Shapiro, Shane J. Cross, Ted H. Morton, Hiroto Inaba, Ashley Holland, Francisca R. Fasipe, and Elisabeth E. AddersonComments to Author 
Author affiliations: St. Jude Children’s Research Hospital, Memphis, Tennessee, USA (K. Shapiro, S.J. Cross, T.H. Morton, H. Inaba, A. Holland, E.E. Adderson); University of Tennessee Health Sciences Center, Memphis (S.J. Cross, T.H. Morton, H. Inaba, E.E. Adderson); Mercy Children’s Hospital, Springfield, Missouri, USA (F.R. Fasipe)

Main Article

Table

Methods of determination and antimicrobial drug susceptibilities of isolates from the current case and published reports of healthcare-associated infections caused by Mycolicibacterium neoaurum*

Reference Method Antimicrobial drug susceptibility†
Case report
 Broth microdilution
 Amikacin, <1, S; cefoxitin, 4, S; ciprofloxacin, <0.12, S; clarithromycin, 8, R; doxycycline, <0.12, S; imipenem, 0.12, S; linezolid, <1, S; moxifloxacin, 0.06, S; tigecycline, 0.12, no interpretation; TMP/SMX, 2/38, S
(6)
 Agar dilution
 Amikacin, 0.5, S; ciprofloxacin, 0.016, S; clarithromycin, 4, I; doxycycline, 0.064, S; linezolid, 0.25, S; meropenem, 0.25, S; moxifloxacin, 0.008, S; TMP/SMX, 0.25, S
(7)
 Etest
 Amikacin, S; clarithromycin, S; TMP/SMX, S
(8)
 Disk diffusion
 Amikacin, S; cefoxitin, S; doxycycline, S; imipenem, S; TMP/SMX, S
(9)
 Etest
 Amikacin, S; cefoxitin, S; ciprofloxacin, S; clarithromycin, S; imipenem, S; linezolid, S; TMP/SMX, R
(10)
 Broth microdilution
 Amikacin, S; cefoxitin, S; ciprofloxacin, S; clarithromycin, R; doxycycline, S; imipenem, S; linezolid, S; moxifloxacin, S; TMP/SMX, S
(11)
 Disk diffusion
 Amikacin, S; cefoxitin, S; ciprofloxacin, S; clarithromycin, R; imipenem, S; TMP/SMX, R
(12)
 Broth microdilution
 Amikacin, <8, S; cefoxitin, <16, S; ciprofloxacin, <1, S; doxycycline, <1, S; imipenem, <2, S; linezolid, <1, S; moxifloxacin, <0.5, S; TMP/SMX, 1/19, S
(13)
 Not reported
 Amikacin, R; ciprofloxacin, R; imipenem, R; TMP/SMX, R
(14)
 Not reported
 Amikacin, <1, S; cefoxitin, 8, S; ciprofloxacin, <0.12, S; clarithromycin, >4, R; doxycycline, <0.25, S
(14)
 Not reported
 Amikacin, 8, S; doxycycline, 0.5, S; linezolid, 1, S
(14)
 Broth microdilution
 Amikacin, 1, S; cefoxitin, 8, S; ciprofloxacin, 0.25, S; clarithromycin, 0.25, S; imipenem, 1, S; linezolid, 2, S
(15)
 Not reported
 Amikacin, <1, S; cefoxitin, 8, S; ciprofloxacin, 0.25, S; clarithromycin, >16, R; doxycycline, 1, S; imipenem, <2, S; linezolid, 4, S; moxifloxacin, <0.25, S; TMP/SMX, 0.5/9.5, S
(16)
 Disk diffusion
 Amikacin, S; ciprofloxacin, S; doxycycline, S; imipenem, S; meropenem, S; TMP/SMX, S
(17)
 Etest
 Ciprofloxacin, S; clarithromycin, R; doxycycline, S; imipenem, S
(18)
 Broth microdilution
 Amikacin, <1.0, S; cefoxitin, 32, I; ciprofloxacin, <0.125, S; clarithromycin, 2, S; doxycycline, <0.125, S; imipenem, 2, S; linezolid, <2, S; moxifloxacin, <0.125, S; TMP/SMX, 16/304, R
(19)
 Not reported
 Amikacin, <8, S; cefoxitin, <16, S; ciprofloxacin, <1, S; clarithromycin, 1, S; doxycycline, <1, S; imipenem, <2, S; linezolid, <1, S; moxifloxacin, <0.5, S; TMP/SMX, <0.5/9.5, S
(20)
 Etest
 Cefoxitin, 2, S; ciprofloxacin, 0.6, S; clarithromycin, 0.125, S; imipenem, 0.19, S; linezolid, 1.5, S; moxifloxacin, 0.2, S; TMP/SMX, 32, R
(21)
 Broth microdilution
 Amikacin, <1, S; cefoxitin, 8, S; clarithromycin, 2, S; imipenem, <2, S; linezolid, 2, S; meropenem, 2, S; moxifloxacin, <0.25, S; TMP/SMX, 1/19, S
(22)
 Disk diffusion
 Amikacin, S; clarithromycin, R; ciprofloxacin, S; doxycycline, S
(23) Etest Imipenem, 0.12, S

*Values for each antimicrobial drug are MICs in μg/mL. Etest, bioMérieux. I, intermediate; S, sensitive; R, resistant; TMP/SMX, trimethoprim/sulfamethoxazole. †MICs were interpreted according to broth microdilution criteria in the Clinical and Laboratory Standards Institute guidelines for rapidly growing mycobacteria (4).

Main Article

References
  1. Gupta  RS, Lo  B, Son  J. Phylogenomics and comparative genomic studies robustly support division of the genus Mycobacterium into an emended genus Mycobacterium and four novel genera. Front Microbiol. 2018;9:67. DOIPubMedGoogle Scholar
  2. Tsukamura  M. A new species of rapidly growing, scotochromogenic mycobacteria, Mycobacterium neoaurum Tsukamura n. sp. [in Japanese]. Med Biol. 1972;85:229–33.
  3. Jeha  S, Pei  D, Choi  J, Cheng  C, Sandlund  JT, Coustan-Smith  E, et al. Improved CNS control of childhood acute lymphoblastic leukemia without cranial irradiation: St Jude Total Therapy Study 16. J Clin Oncol. 2019;37:3377–91. DOIPubMedGoogle Scholar
  4. Clinical and Laboratory Standards Institute. Susceptibility testing of mycobacteria, Nocardia spp., and other aerobic actinomycetes, 3rd edition (M24-3E). Wayne (PA): The Institute; 2018.
  5. Mermel  LA, Allon  M, Bouza  E, Craven  DE, Flynn  P, O’Grady  NP, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;49:1–45. DOIPubMedGoogle Scholar
  6. Hayton  ER, Koch  O, Scarborough  M, Sabharwal  N, Drobniewski  F, Bowler  ICJW. Rapidly growing mycobacteria as emerging pathogens in bloodstream and device-related infection: a case of pacemaker infection with Mycobacterium neoaurum. JMM Case Rep. 2015;2:1–3. DOIGoogle Scholar
  7. Baird  SF, Taori  SK, Dave  J, Willocks  LJ, Roddie  H, Hanson  M. Cluster of non-tuberculous mycobacteraemia associated with water supply in a haemato-oncology unit. J Hosp Infect. 2011;79:339–43. DOIPubMedGoogle Scholar
  8. Davison  MB, McCormack  JG, Blacklock  ZM, Dawson  DJ, Tilse  MH, Crimmins  FB. Bacteremia caused by Mycobacterium neoaurum. J Clin Microbiol. 1988;26:762–4. DOIPubMedGoogle Scholar
  9. Rubia  MF, Chozas  N, García-Martos  P, Reyes  F. [Mycobacterium neoaurum bacteremia in an immunodepressed patient] [in Spanish]. Enferm Infecc Microbiol Clin. 2009;27:58–9. DOIPubMedGoogle Scholar
  10. Hawkins  C, Qi  C, Warren  J, Stosor  V. Catheter-related bloodstream infections caused by rapidly growing nontuberculous mycobacteria: a case series including rare species. Diagn Microbiol Infect Dis. 2008;61:187–91. DOIPubMedGoogle Scholar
  11. Holland  DJ, Chen  SC, Chew  WW, Gilbert  GL. Mycobacterium neoaurum infection of a Hickman catheter in an immunosuppressed patient. Clin Infect Dis. 1994;18:1002–3. DOIPubMedGoogle Scholar
  12. Moseley  JE Jr, Thind  SK. Mycobacterium neoaurum bloodstream infection associated with a totally implanted subclavian port in an adult with diabetes and history of colon cancer. Case Rep Infect Dis. 2020;2020:8878069. DOIPubMedGoogle Scholar
  13. Pang  L, Chen  Z, Xu  D, Cheng  W. Case report: Mycobacterium neoaurum infection during ICI therapy in a hepatocellular carcinoma patient with psoriasis. Front Immunol. 2022;13:972302. DOIPubMedGoogle Scholar
  14. van Duin  D, Goldfarb  J, Schmitt  SK, Tomford  JW, Tuohy  MJ, Hall  GS. Nontuberculous mycobacterial blood stream and cardiac infections in patients without HIV infection. Diagn Microbiol Infect Dis. 2010;67:286–90. DOIPubMedGoogle Scholar
  15. Walayat  S, Awwal  T, Roy  M, Ahmad  S. Mycobacterium neoaurum line-related bacteremia with pulmonary involvement: Case report and review of literature. IDCases. 2018;11:88–90. DOIPubMedGoogle Scholar
  16. Woo  PC, Tsoi  HW, Leung  KW, Lum  PN, Leung  AS, Ma  CH, et al. Identification of Mycobacterium neoaurum isolated from a neutropenic patient with catheter-related bacteremia by 16S rRNA sequencing. J Clin Microbiol. 2000;38:3515–7. DOIPubMedGoogle Scholar
  17. Becker  ML, Suchak  AA, Wolfe  JN, Zarychanski  R, Kabani  A, Nicolle  LE. Mycobacterium neoaurum bacteremia in a hemodialysis patient. Can J Infect Dis. 2003;14:45–8. DOIPubMedGoogle Scholar
  18. Kim  CK, Choi  SI, Jeon  BR, Lee  YW, Lee  YK, Shin  HB. Pulmonary infection caused by Mycobacterium neoaurum: the first case in Korea. Ann Lab Med. 2014;34:243–6. DOIPubMedGoogle Scholar
  19. Morimoto  Y, Chan  ED, Heifets  L, Routes  JM. Pulmonary infection with Mycobacterium neoaurum identified by 16S ribosomal DNA sequence. J Infect. 2007;54:e227–31. DOIPubMedGoogle Scholar
  20. Bastón-Paz  N, Bolaños-Rivero  M, Hernández-Cabrera  M, Martín-Sánchez  AM. [Pacemaker infection with Mycobacterium neoaurum.] [in Spanish]. Rev Esp Quimioter. 2018;31:379–82.PubMedGoogle Scholar
  21. Kusano  T, Fukasawa  C, Yamamoto  S, Shiratori  E, Murata  S, Takaki  A, et al. Pin tract infection caused by Mycobacterium neoaurum in a 14-year-old child: A case report. J Infect Chemother. 2021;27:1244–7. DOIPubMedGoogle Scholar
  22. McNally  CF, Mangino  JE. Mycobacterium neoaurum: a case report and review of the literature. Infect Dis Clin Pract. 2000;9:273–5. DOIGoogle Scholar
  23. Zanetti  S, Faedda  R, Fadda  G, Dupré  I, Molicotti  P, Ortu  S, et al. Isolation and identification of Mycobacterium neoaurum from a patient with urinary infection. New Microbiol. 2001;24:189–92.PubMedGoogle Scholar
  24. Pérez-Cortés Villalobos  A, Rotstein  C. Mycobacterium mucogenicum and Mycobacterium neoaurum bacteremia in immunocompromised hosts. J Assoc Med Microbiol Infect Dis Can. 2021;6:55–62. DOIPubMedGoogle Scholar
  25. Redelman-Sidi  G, Sepkowitz  KA. Rapidly growing mycobacteria infection in patients with cancer. Clin Infect Dis. 2010;51:422–34. DOIPubMedGoogle Scholar
  26. Daley  CL, Iaccarino  JM, Lange  C, Cambau  E, Wallace  RJ Jr, Andrejak  C, et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. Clin Infect Dis. 2020;71:905–13. DOIPubMedGoogle Scholar
  27. Philips  RC, Hoyer  PE, White  SM, Tinkey  KT, Loeffelholz  M, Andersen  CR, et al. Cutaneous nontuberculous mycobacteria infections: A retrospective case series of 78 patients from the Texas Gulf Coast region. J Am Acad Dermatol. 2019;81:730–9. DOIPubMedGoogle Scholar
  28. Dorman  SE, Picard  C, Lammas  D, Heyne  K, van Dissel  JT, Baretto  R, et al. Clinical features of dominant and recessive interferon gamma receptor 1 deficiencies. Lancet. 2004;364:2113–21. DOIPubMedGoogle Scholar
  29. Heckman  GA, Hawkins  C, Morris  A, Burrows  LL, Bergeron  C. Rapidly progressive dementia due to Mycobacterium neoaurum meningoencephalitis. Emerg Infect Dis. 2004;10:924–7. DOIPubMedGoogle Scholar
  30. Han  XY. Mycobacterium neoaurum contamination. Emerg Infect Dis. 2005;11:1316–7, author reply 1317. DOIPubMedGoogle Scholar
  31. Padya  L, Chin’ombe  N, Magwenzi  M, Mbanga  J, Ruhanya  V, Nziramasanga  P. Molecular identification of Mycobacterium species of public health importance in cattle in Zimbabwe by 16S rRNA gene sequencing. Open Microbiol J. 2015;9:38–42. DOIPubMedGoogle Scholar
  32. Puk  K, Guz  L. Occurrence of Mycobacterium spp. in ornamental fish. Ann Agric Environ Med. 2020;27:535–9. DOIPubMedGoogle Scholar
  33. Sevilla  IA, Molina  E, Tello  M, Elguezabal  N, Juste  RA, Garrido  JM. Detection of mycobacteria by culture and DNA-based methods in animal-derived food products purchased at Spanish supermarkets. Front Microbiol. 2017;8:1030. DOIPubMedGoogle Scholar
  34. Desai  AN, Hurtado  RM. Infections and outbreaks of nontuberculous mycobacteria in hospital settings. Curr Treat Options Infect Dis. 2018;10:169–81. DOIPubMedGoogle Scholar
  35. Kaevska  M, Sterba  J, Svobodova  J, Pavlik  I. Mycobacterium avium subsp. avium and Mycobacterium neoaurum detection in an immunocompromised patient. Epidemiol Infect. 2014;142:882–5. DOIPubMedGoogle Scholar
  36. Ransom  EM, Alipour  Z, Wallace  MA, Burnham  CA. Evaluation of optimal blood culture incubation time to maximize clinically relevant results from a contemporary blood culture instrument and media system. J Clin Microbiol. 2021;59:e02459–20. DOIPubMedGoogle Scholar
  37. Brown-Elliott  BA, Woods  GL. Antimycobacterial susceptibility testing of nontuberculous mycobacteria. J Clin Microbiol. 2019;57:e00834–19. DOIPubMedGoogle Scholar
  38. Huang  WC, Yu  MC, Huang  YW. Identification and drug susceptibility testing for nontuberculous mycobacteria. J Formos Med Assoc. 2020;119(Suppl 1):S32–41. DOIPubMedGoogle Scholar
  39. El Helou  G, Viola  GM, Hachem  R, Han  XY, Raad  II. Rapidly growing mycobacterial bloodstream infections. Lancet Infect Dis. 2013;13:166–74. DOIPubMedGoogle Scholar
  40. Martín-de-Hijas  NZ, García-Almeida  D, Ayala  G, Fernández-Roblas  R, Gadea  I, Celdrán  A, et al. Biofilm development by clinical strains of non-pigmented rapidly growing mycobacteria. Clin Microbiol Infect. 2009;15:931–6. DOIPubMedGoogle Scholar
  41. Brown-Elliott  BA, Wallace  RJ Jr, Petti  CA, Mann  LB, McGlasson  M, Chihara  S, et al. Mycobacterium neoaurum and Mycobacterium bacteremicum sp. nov. as causes of mycobacteremia. J Clin Microbiol. 2010;48:4377–85. DOIPubMedGoogle Scholar
  42. Ilinov  A, Nishiyama  A, Namba  H, Fukushima  Y, Takihara  H, Nakajima  C, et al. Extracellular DNA of slow growers of mycobacteria and its contribution to biofilm formation and drug tolerance. Sci Rep. 2021;11:10953. DOIPubMedGoogle Scholar
  43. Karol  SE, Sun  Y, Tang  L, Pui  CH, Ferrolino  J, Allison  KJ, et al. Fluoroquinolone prophylaxis does not increase risk of neuropathy in children with acute lymphoblastic leukemia. Cancer Med. 2020;9:6550–5. DOIPubMedGoogle Scholar

Main Article

Page created: June 02, 2023
Page updated: July 14, 2023
Page reviewed: July 14, 2023
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external